Nutritional and Metabolic liver disease
- Page Path
-
- HOME
- TOPICS
- Nutritional and Metabolic liver disease
- Letter to the Editor
- Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
- Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
- Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022
-
View: 6632 Download: 395 Web of Science: 15 Crossref: 15
- Review
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
- Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
- Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021
-
View: 9637 Download: 395 Web of Science: 68 Crossref: 67
- Editorial
- Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
- Sooyeon Oh, Jooho Lee
- Clin Mol Hepatol. 2020;26(4):476-479. Published online October 1, 2020
-
View: 6188 Download: 168 Web of Science: 12 Crossref: 11
- Original Article
- Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals
- Yvelise Ferro, Ilaria Carè, Elisa Mazza, Francesco Provenzano, Carmela Colica, Carlo Torti, Stefano Romeo, Arturo Pujia, Tiziana Montalcini
- Clin Mol Hepatol. 2017;23(3):249-259. Published online July 28, 2017
-
View: 14236 Download: 161 Web of Science: 24 Crossref: 23
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor14.0First decision
07 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2023-2025)
|
|||||||
